公开(公告)号：EP3889172A1

公开(公告)日：2021-10-06

申请号：EP21165709.3

申请日：2015-02-10

申请人： Merck Patent GmbH

发明人： LO, Kin-Ming

IPC分类号： C07K14/71 ,  C07K16/22 ,  C07K16/28 ,  C07K16/46 ,  C07K19/00

摘要： This invention relates generally to bifunctional molecules including (a) a TGFβRII or fragment thereof capable of binding TGFβ and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules.

公开(公告)号：EP3105246A2

公开(公告)日：2016-12-21

申请号：EP15717097.8

申请日：2015-02-10

申请人： Merck Patent GmbH

发明人： LO, Kin-Ming

IPC分类号： C07K14/71 ,  C07K16/22 ,  C07K16/28 ,  C07K16/46 ,  C07K19/00

CPC分类号： C07K16/2896 ,  A61K38/177 ,  A61K39/3955 ,  A61K2039/505 ,  C07K14/495 ,  C07K14/71 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K2319/00 ,  C07K2319/33

摘要： This invention relates generally to bifunctional molecules including (a) a TGFβRII or fragment thereof capable of binding TGFβ and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules.

摘要翻译： 本发明一般涉及双功能分子，包括（a）能够结合TGFβb的TGFβbII; RII或其片段; 和（b）结合免疫检查点蛋白的抗体或其抗原结合片段，例如程序性死亡配体1（PD-L1），这种分子的用途（例如，用于治疗癌症），以及制备其的方法 分子。

公开(公告)号：EP1572748B1

公开(公告)日：2010-06-23

申请号：EP03795898.0

申请日：2003-12-16

申请人： Merck Patent GmbH

发明人： GILLIES, Stephen, D. ,  LO, Kin-Ming

IPC分类号： C07K16/30 ,  C12N15/13 ,  C12N5/10 ,  C07K19/00 ,  A61K39/395 ,  C07K16/46

CPC分类号： C07K16/3084 ,  A61K48/00 ,  C07K16/30 ,  C07K16/467 ,  C07K2317/24 ,  C07K2317/732

摘要： The invention provides humanized antibody H14.18 binding the human cell surface glycosphingolipid GD2. The antibody comprises modified variable regions, more specially, modified framework regions, which reduce their immunogenitity when administered to a human. The antibody may be coupled to the therapeutic agent such as IL-2 and used in the treatment of cancer.

公开(公告)号：EP1966244B1

公开(公告)日：2012-03-21

申请号：EP06829726.6

申请日：2006-12-19

申请人： Merck Patent GmbH

发明人： WAY, Jeffrey C. ,  GILLIES, Stephen D. ,  LO, Kin-Ming ,  LIU, Yuan

IPC分类号： C07K16/24 ,  A61K39/395 ,  A61P35/00 ,  C12N15/13 ,  C07K19/00 ,  C07K14/54

CPC分类号： C07K14/5412 ,  A61K2039/505 ,  C07K14/7155 ,  C07K16/248 ,  C07K16/2866 ,  C07K16/3023 ,  C07K16/3053 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30

摘要： The present invention provides anti IL-6 antibodies including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.

公开(公告)号：EP1383785B1

公开(公告)日：2011-03-16

申请号：EP02769304.3

申请日：2002-05-03

申请人： Merck Patent GmbH

发明人： GILLIES, Stephen, D. ,  LO, Kin-Ming ,  QIAN, Xiuqi

IPC分类号： C07K16/30 ,  C07K16/46

CPC分类号： C07K16/46 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/24 ,  C07K2319/00 ,  C07K2319/30

摘要： The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies, when coupled to the appropriate moiety, may be used in the diagnosis, prognosis and treatment of cancer.

公开(公告)号：EP1761559B1

公开(公告)日：2009-09-23

申请号：EP05766761.0

申请日：2005-06-28

申请人： Merck Patent GmbH

发明人： GILLIES, Stephen, D. ,  WATKINS, Nigel, John ,  BAKER, Matthew, Paul ,  LO, Kin-Ming

IPC分类号： C07K14/565

CPC分类号： C07K16/46 ,  A61K38/00 ,  A61K47/48423 ,  A61K47/6813 ,  C07K14/565 ,  C07K2319/30

摘要： Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc- IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.

公开(公告)号：EP1966238A1

公开(公告)日：2008-09-10

申请号：EP06846989.9

申请日：2006-12-20

申请人： Merck Patent GmbH

发明人： WEBSTER, Gordon D. ,  MCKENZIE, Suzanne P. ,  LO, Kin-Ming ,  STEIN, Pascal André

IPC分类号： C07K14/54 ,  A61K38/20 ,  C12N15/24 ,  C12N15/62 ,  C12N5/00

CPC分类号： H04N21/4353 ,  A61K38/00 ,  C07K14/5434 ,  G06Q20/10 ,  G06Q30/0215 ,  G06Q30/0226 ,  G06Q30/04 ,  G06Q40/12 ,  H04L41/32 ,  H04L41/5019 ,  H04L47/2491 ,  H04N21/462 ,  H04N21/6106 ,  H04N21/8549

摘要： Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.

公开(公告)号：EP1366067A2

公开(公告)日：2003-12-03

申请号：EP02717581.9

申请日：2002-03-07

申请人： MERCK PATENT GmbH

发明人： GILLIES, Stephen, D. ,  WAY, Jeffrey ,  LO, Kin-Ming

IPC分类号： C07K14/00 ,  C07K16/00 ,  A61K39/44 ,  C07H21/04 ,  C12P21/06

CPC分类号： C07K16/30 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2319/00 ,  C07K2319/30

摘要： Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.

公开(公告)号：EP1107989B1

公开(公告)日：2010-03-31

申请号：EP99942468.2

申请日：1999-08-25

申请人： Merck Patent GmbH

发明人： LO, Kin-Ming ,  LI, Yue ,  GILLIES, Stephen, D.

IPC分类号： C07K14/78 ,  C07K14/515 ,  C12N9/68 ,  C12N15/62 ,  C07K19/00

CPC分类号： A61K38/00 ,  C07K14/515 ,  C07K14/78 ,  C07K2317/24 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/75 ,  C12N9/6435 ,  C12N15/62 ,  C12Y304/21007 ,  Y10S530/81

摘要： Disclosed are nucleotide sequences, for example, DNA or RNA sequences, which encode an immunoglobulin Fc-angiogenesis inhibitor fusion protein. The angiogenesis inhibitors can be angiostatin, endostatin, a plasminogen fragment having angiostatin activity, or a collagen XVIII fragment having endostatin activity. The nucleotide sequences can be inserted into a suitable expression vector and expressed in mammalian cells. Also disclosed is a family of immunoglobulin Fc-angiogenesis inhibitor fusion proteins that can be produced by expression of such nucleotide sequences. Also disclosed are methods using such nucleotide sequences and fusion proteins for treating conditions mediated by angiogenesis.

公开(公告)号：EP1228214A2

公开(公告)日：2002-08-07

申请号：EP00984954.8

申请日：2000-11-03

申请人： MERCK PATENT GmbH

发明人： HARTMANN, Arno ,  BRANDT, Silke ,  RIEKE, Erwin ,  SOBEL, Cornelius ,  LO, Kin-Ming ,  WAY, Jeffrey, C. ,  GILLIES, Stephen

IPC分类号： C12N15/18

CPC分类号： C07K14/505 ,  A61K38/00 ,  A61K47/6811 ,  C07K2319/00 ,  C07K2319/30

摘要： The invention relates to novel modified erythropoietin (EPO) forms such as fusion proteins comprising a Fc portion of an Ig molecule and a target molecule having the biological activity of EPO. By selective altering of the amino acid sequences of the erythropoietin moiety as well as of the immunoglobulin moiety and the glycosylation pattern of erythropoietin fusion proteins with enhanced biological activity can be obtained. The invention relates also to novel non-fused EPO molecules which have a pattern of cysteines or disulfide bonding which is distinct from human or animal EPO.